Why Aptinyx Stock Is Soaring Today

What happened

Shares of the clinical-stage biotech Aptinyx (NASDAQ: APTX) are up by an eye-catching 55% as of 9:55 a.m. Tuesday morning. The drugmaker's stock is ripping higher in response to a positive midstage trial for its post-traumatic stress disorder (PTSD) candidate known as NYX-783.

Before the opening bell, Aptinyx announced that NYX-783 exhibited statistically significant and clinically meaningful efficacy results in a midstage trial consisting of 153 patients with PTSD. Equally as important, the company also reported that the drug showed a favorable adverse event and tolerability profile in the study.

A man standing in front of a pink background and wearing sunglasses throwing money into the air

Image source: Getty Images.

So what

PTSD affects over 8.5 million Americans. Yet there are no drugs currently on the market that treat the underlying cause of this serious disorder. Aptinyx is hoping to change this situation for the better with NYX-783. Specifically, this novel NMDA receptor modulator is designed to target the root cause of PTSD, not simply alleviate symptoms associated with this disorder.

So, in short, Aptinyx might have a major new drug on its hands -- perhaps one capable of generating blockbuster-level sales following approval (greater than $1 billion a year). That's a huge deal for a company with a market cap of only $263 million at the time of writing.

Now what

Aptinyx plans on discussing a registrational trial for the drug with regulators soon. So, if things go according to plan, NYX-783 may be in a late-stage study as soon as mid-2021. This small-cap biotech, in turn, will more than likely take advantage of this spike in its share price to raise funds for this upcoming trial. Phase 3 trials, after all, are an expensive endeavor.

10 stocks we like better than Aptinyx Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Aptinyx Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of September 24, 2020

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More